secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVITA Medical, Inc. (RCEL)
CIK:        0001762303
Form:       8-K
Filed at:   2025-01-07T23:59:59+00:00
Accession:  0000950170-25-002907
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AVITA Medical slashes Q4 2024 revenue outlook to ~$18.4M; profitability pushed to Q4 2025
--------------------------------------------------------------------------------

- Q4 2024 commercial revenue expected ~$18.4M (30% YoY growth) vs prior guidance of $22.3-24.3M.
- Full-year 2024 revenue now ~$64.3M (29% YoY growth) vs prior $68-70M.
- FY 2025 revenue guidance $100-106M (55-65% growth).
- Cashflow breakeven and GAAP profitability now expected in Q4 2025, delayed from Q3 2025.
- Miss attributed to slower hospital year-end purchasing; new products RECELL GO and Cohealyx remain growth drivers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1762303/000095017025002907/0000950170-25-002907-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1762303/000095017025002907/rcel-20250107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-002907

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer